Profile data is unavailable for this security.
About the company
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
- Revenue in USD (TTM)21.61m
- Net income in USD-35.43m
- Incorporated2011
- Employees13.00
- LocationXOMA Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 204-7239
- Fax+1 (302) 655-5049
- Websitehttps://www.xoma.com/
More ▼
Mergers & acquisitions
| Acquired company | XOMA:NMQ since announced | Transaction value |
|---|---|---|
| Kinnate Biopharma Inc | 40.04% | 99.33m |
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kodiak Sciences Inc | 0.00 | -191.62m | 325.69m | 108.00 | -- | 1.76 | -- | -- | -3.65 | -3.65 | 0.00 | 3.52 | 0.00 | -- | -- | 0.00 | -41.64 | -31.73 | -46.43 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Silence Therapeutics plc | 22.43m | -50.25m | 327.09m | 115.00 | -- | 5.48 | -- | 14.58 | -0.4040 | -0.4040 | 0.1792 | 1.00 | 0.1273 | -- | 2.56 | 195,058.90 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.53m | 330.78m | 45.00 | -- | 3.95 | -- | -- | -4.75 | -4.75 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -60.56 | -- | -68.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| AC Immune SA | 45.85m | -44.60m | 334.42m | 133.00 | -- | 2.30 | -- | 7.29 | -0.4571 | -0.4571 | 0.4744 | 1.47 | 0.2116 | -- | 3.19 | 344,710.40 | -20.59 | -18.25 | -29.04 | -19.52 | -- | -- | -97.29 | -148.29 | -- | -14.57 | 0.0231 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 339.58m | 33.00 | -- | 1.47 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| AVITA Medical Inc | 60.04m | -57.32m | 349.74m | 207.00 | -- | 28.60 | -- | 5.83 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.60m | -75.96m | 352.26m | 25.00 | -- | -- | -- | 220.71 | -0.0631 | -0.0631 | 0.0013 | -0.0499 | 0.0525 | -- | -- | 63,840.00 | -244.93 | -381.58 | -- | -- | -- | -- | -4,666.29 | -6,479.25 | -- | -27.91 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| XOMA Royalty Corp | 21.61m | -35.43m | 355.84m | 13.00 | -- | 4.19 | -- | 16.47 | -3.06 | -3.06 | 1.86 | 7.21 | 0.1244 | -- | 39.72 | 1,662,000.00 | -17.25 | -4.55 | -18.97 | -4.94 | -- | -- | -138.67 | -31.87 | -- | -- | 0.5817 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Contineum Therapeutics Inc | 0.00 | -35.46m | 363.21m | 31.00 | -- | 1.72 | -- | -- | -1.39 | -1.39 | 0.00 | 8.17 | 0.00 | -- | -- | 0.00 | -19.97 | -- | -20.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Codexis Inc | 64.45m | -62.09m | 375.15m | 174.00 | -- | 5.11 | -- | 5.82 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| ProQR Therapeutics NV | 22.21m | -24.94m | 383.37m | 157.00 | -- | 11.72 | -- | 17.26 | -0.3059 | -0.3059 | 0.2724 | 0.3089 | 0.1713 | -- | -- | 141,438.90 | -19.24 | -35.51 | -26.22 | -40.51 | -- | -- | -112.31 | -926.31 | -- | -- | 0.4105 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Prime Medicine Inc | 800.00k | -219.25m | 384.10m | 234.00 | -- | 2.21 | -- | 480.12 | -2.05 | -2.05 | 0.0073 | 1.44 | 0.0028 | -- | -- | 3,418.80 | -76.67 | -- | -88.64 | -- | -- | -- | -27,406.13 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Alector Inc | 61.51m | -158.41m | 385.85m | 241.00 | -- | 3.24 | -- | 6.27 | -1.71 | -1.71 | 0.6607 | 1.21 | 0.1035 | -- | -- | 252,082.00 | -26.66 | -20.00 | -35.58 | -23.81 | -- | -- | -257.54 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Sangamo Therapeutics Inc | 52.29m | -134.84m | 391.45m | 405.00 | -- | 10.02 | -- | 7.49 | -0.7079 | -0.7079 | 0.2696 | 0.1876 | 0.316 | -- | 8.98 | 129,113.60 | -81.48 | -26.09 | -112.69 | -31.04 | -- | -- | -257.86 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 393.05m | 42.00 | -- | 1.98 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Data as of Nov 25 2024. Currency figures normalised to XOMA Royalty Corp's reporting currency: US Dollar USD
56.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2024 | 3.63m | 31.05% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 1.04m | 8.93% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 492.23k | 4.21% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 410.24k | 3.51% |
| Opaleye Management, Inc.as of 30 Sep 2024 | 250.00k | 2.14% |
| Stonepine Capital Management LLCas of 30 Sep 2024 | 195.10k | 1.67% |
| Geode Capital Management LLCas of 30 Sep 2024 | 182.74k | 1.56% |
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 151.78k | 1.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 142.86k | 1.22% |
| TLS Advisors LLCas of 30 Sep 2024 | 119.74k | 1.02% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
